Arvinas to present phase 1 data for ARV-102 Parkinson's drug at conference

March 11, 2026 7:00 AM

Arvinas Inc. (NASDAQ: ARVN) will present phase 1 clinical trial data for ARV-102, an investigational drug for Parkinson's disease, at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found